<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VERSACLOZ- clozapine suspension </strong><br>Jazz Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VERSACLOZ<span class="Sup">®</span> safely and effectively. See full prescribing information for VERSACLOZ<span class="Sup">®</span>. <br><br>VERSACLOZ (clozapine) oral suspension<br>Initial U.S. Approval: 1989</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></h1>
<h1 class="Warning"> </h1>
<p class="Highlighta"><span class="Italics">See full prescribing information for complete boxed warning.</span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: Clozapine can cause severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, which can lead to serious and fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Patients initiating and continuing treatment with VERSACLOZ must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment (<a href="#i4i_section_id_13a77ed2-fe7f-45d6-8e7c-eaefdea0caeb">2.1</a>, <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">5.1</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold">VERSACLOZ is available only through a restricted program called the Clozapine REMS (<a href="#i4i_section_id_4521df88-52ae-4448-aa3c-eec77b0f7e13">5.2</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>, <a href="#i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803">2.6</a>, <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">5.3</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>, <a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">5.4</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions (<a href="#i4i_section_id_5fc47f63-7d6f-42d8-a4be-d26fe45faa0d">5.5</a>).</span></dd>
<dt>•</dt>
<dd><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: VERSACLOZ is not approved for this condition (<a href="#i4i_section_id_ace9148a-5bbd-492d-8a3b-0e65509e5451">5.6</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="87%">
<col width="13%">
<tbody class="Headless">
<tr>
<td class="Toprule" valign="top"><dl>
<dt>•</dt>
<dd>Indications and Usage (<a href="#i4i_section_id_1625a63b-95b1-41aa-8401-6369ec72dee7">1.1</a>)</dd>
</dl></td>
<td class="Toprule" align="center" valign="top"><p class="Highlighta">9/2015 </p></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd>Boxed Warning, Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></dd>
</dl></td>
<td align="center" valign="top"><p class="Highlighta">9/2015 </p></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd>Dosage and Administration, Required Laboratory Testing Prior to Initiation and During Therapy (<a href="#i4i_section_id_13a77ed2-fe7f-45d6-8e7c-eaefdea0caeb">2.1</a>), Discontinuation of Treatment (<a href="#i4i_section_id_b98d7c3d-1c53-4813-805b-05606f7f5289">2.5</a>)</dd>
</dl></td>
<td align="center" valign="top"><p class="Highlighta">9/2015 </p></td>
</tr>
<tr>
<td valign="top"><dl>
<dt>•</dt>
<dd>Contraindications, History of Clozapine-induced <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> or Severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span> (<a href="#i4i_section_id_eb7d589a-ba4e-4c59-a274-42a834d32a03">4.1</a>), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#i4i_section_id_eb7d589a-ba4e-4c59-a274-42a834d32a03">4.1</a>)</dd>
</dl></td>
<td align="center" valign="top"><p class="Highlighta">9/2015 </p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><dl>
<dt>•</dt>
<dd>Warnings and Precautions, Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (<a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">5.1</a>), Clozapine REMS Program (<a href="#i4i_section_id_4521df88-52ae-4448-aa3c-eec77b0f7e13">5.2</a>)</dd>
</dl></td>
<td class="Botrule" align="center" valign="top"><p class="Highlighta">9/2015 </p></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></h1>
<h1 class="Warning"> </h1>
<p class="Highlighta"><span class="Italics">See full prescribing information for complete boxed warning.</span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: Clozapine can cause severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, which can lead to serious and fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Patients initiating and continuing treatment with VERSACLOZ must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment (<a href="#i4i_section_id_13a77ed2-fe7f-45d6-8e7c-eaefdea0caeb">2.1</a>, <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">5.1</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold">VERSACLOZ is available only through a restricted program called the Clozapine REMS (<a href="#i4i_section_id_4521df88-52ae-4448-aa3c-eec77b0f7e13">5.2</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>, <a href="#i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803">2.6</a>, <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">5.3</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>, <a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">5.4</a>). </span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions (<a href="#i4i_section_id_5fc47f63-7d6f-42d8-a4be-d26fe45faa0d">5.5</a>).</span></dd>
<dt>•</dt>
<dd><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: VERSACLOZ is not approved for this condition (<a href="#i4i_section_id_ace9148a-5bbd-492d-8a3b-0e65509e5451">5.6</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VERSACLOZ is an atypical antipsychotic indicated for:  </p>
<dl>
<dt>•</dt>
<dd>Treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Efficacy was established in an active-controlled study (<a href="#i4i_section_id_1625a63b-95b1-41aa-8401-6369ec72dee7">1.1</a>, <a href="#i4i_section_id_1165a096-9a8b-42cb-a62f-f99ede2555d7">14.1</a>).</dd>
<dt>•</dt>
<dd>Reducing <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>. Efficacy was established in an active-controlled study (<a href="#i4i_section_id_90d6c543-da97-4726-a898-6f6158490022">1.2</a>, <a href="#i4i_section_id_f390cb8d-d78a-45d1-9f52-9269e58c9d79">14.2</a>).</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Starting Dose: 12.5 mg once daily or twice daily (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>).</dd>
<dt>•</dt>
<dd>Use cautious titration and divided dosage schedule (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>, <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">5.3</a>).</dd>
<dt>•</dt>
<dd>Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>).</dd>
<dt>•</dt>
<dd>Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>).</dd>
<dt>•</dt>
<dd>Subsequent increases: increase in increments of 100 mg or less, once or twice weekly (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>).</dd>
<dt>•</dt>
<dd>Maximum daily dose: 900 mg (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>).</dd>
<dt>•</dt>
<dd>Administer orally using syringe provided (<a href="#i4i_section_id_d03dec5d-446e-4f17-92f7-a1035c497719">2.3</a>). </dd>
<dt>•</dt>
<dd>Shake bottle for 10 seconds prior to withdrawing suspension from bottle; use oral syringes and syringe adaptor provided (<a href="#i4i_section_id_d03dec5d-446e-4f17-92f7-a1035c497719">2.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Oral suspension: 50 mg per mL (<a href="#i4i_dosage_form_strength_id_8ce48dd6-b6ea-4bd7-8399-2fef322051e9">3</a>).</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clozapine or any other component of VERSACLOZ (<a href="#_Ref">4.1</a>).</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>:</span> Assess for organ involvement (e.g., <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>). Discontinue if these occur (<a href="#i4i_section_id_39fa211a-87d7-4869-90ff-2b053c9f4fe7">5.7</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics">QT Interval Prolongation:</span> Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs) (<a href="#i4i_section_id_2abb5581-d2b8-4aa2-b803-4e5cf73a4e7b">5.8</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics">Metabolic Changes:</span> Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:<dl>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus: </span>Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Monitor glucose regularly in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (<a href="#i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46">5.9</a>). </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>: </span> Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics (<a href="#i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46">5.9</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:</span> Significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has occurred. Monitor <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (<a href="#i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46">5.9</a>).</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS):</span> Immediately discontinue and monitor closely. Assess for co-morbid conditions (<a href="#i4i_section_id_18276b32-9318-48bf-b5b5-2141660e9fca">5.10</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>:</span> Evaluate for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, NMS (<a href="#i4i_section_id_875c48ff-3ac3-4a1b-9d62-5149b804f87a">5.11</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE):</span> Consider PE if <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, chest, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, or <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> occurs (<a href="#i4i_section_id_2cbc7301-c238-482c-9a0d-460b6ad982ef">5.12</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics">Anticholinergic Toxicity:</span> Use cautiously in presence of specific conditions (e.g., narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, use of anticholinergic drugs) (<a href="#i4i_section_id_0986f3d4-d5d4-45d4-b38f-dffbf4cb2c26">5.13</a>).</dd>
<dt>•</dt>
<dd>
<span class="Italics">Interference with Cognitive and Motor Performance:</span> Advise caution when operating machinery, including automobiles (<a href="#i4i_section_id_5f1218f8-ee95-41e3-9999-64e3a0d73782">5.14</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥5%) were: CNS reactions (sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>); cardiovascular reactions (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>); autonomic nervous system reactions (<span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>); gastrointestinal reactions (<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>); and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (<a href="#i4i_section_id_2d19c6d4-4f3c-4194-b978-a8cfcf33690c">6.1</a>).<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals at 1-800-520-5568 or FDA at 1-800-FDA-1088 or <a href="#_Ref">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Concomitant use of <span class="Italics">Strong CYP1A2 Inhibitors</span>: Reduce VERSACLOZ dose to one third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) (<a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">2.7</a>, <a href="#i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb">7.1</a>).</dd>
<dt>•</dt>
<dd>Concomitant use of <span class="Italics">Strong CYP3A4 Inducers </span>is not recommended (<a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">2.7</a>, <a href="#i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb">7.1</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Discontinuation of CYP1A2 or CYP3A4 Inducers</span>: Consider reducing VERSACLOZ dose when CYP1A2 (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued (<a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">2.7</a>, <a href="#i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb">7.1</a>).</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Nursing Mothers</span>: Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother (<a href="#i4i_nursing_mothers_id_cdbdf840-e375-478d-9926-daa624f42b98">8.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="XmChange">1.1 Treatment-Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Reduction in the Risk of Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorders</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="XmChange">2.1 Required Laboratory Testing Prior to Initiation and During Therapy</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing Information  </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Important Administration Instructions  </a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Maintenance Treatment</a></h2>
<h2><a href="#section-2.5" class="toc"><span class="XmChange">2.5 Discontinuation of Treatment</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Re-Initiation of Treatment  </a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers  </a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>, or CYP2D6 Poor Metabolizers</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc"><span class="XmChange">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="XmChange">5.2 Clozapine REMS Program</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 QT Interval Prolongation</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Metabolic Changes</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Anticholinergic Toxicity</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></a></h2>
<h2><a href="#section-5.16" class="toc"> 5.16 Cerebrovascular Adverse Reactions </a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> and Cholinergic Rebound after Abrupt Discontinuation of VERSACLOZ</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for Other Drugs to Affect VERSACLOZ</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for VERSACLOZ to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 CYP2D6 Poor Metabolizers</a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Hospice Patients </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Overdosage Experience</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Management of Overdosage</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Treatment-Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="_Toc362876057"></a><a name="section-1"></a><p></p>
<h1>WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">ORTHOSTATIC HYPOTENSION</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>, AND <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">SYNCOPE</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">SEIZURE</span>; <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">MYOCARDITIS</span> AND <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>; INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></h1>
<p class="First"><span class="Bold"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></span></p>
<p><span class="Bold">Clozapine treatment has caused severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, defined as an absolute neutrophil count (ANC) less than 500/µL. Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Prior to initiating treatment with VERSACLOZ a baseline ANC must be at least 1500/µL for the general population, and must be at least 1000/µL for patients with documented Benign Ethnic <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (BEN). During treatment, patients must have regular ANC monitoring. Advise patients to immediately report symptoms consistent with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>)<span class="Italics"> [see <a href="#i4i_section_id_13a77ed2-fe7f-45d6-8e7c-eaefdea0caeb">Dosage and Administration (2.1)</a> and <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1)</a>].</span></span><br></p>
<p><span class="Bold">Because of the risk of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, VERSACLOZ is available only through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program <span class="Italics">[see <a href="#i4i_section_id_4521df88-52ae-4448-aa3c-eec77b0f7e13">Warnings and Precautions (5.2)</a>].</span></span><br></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages. Use VERSACLOZ cautiously in patients with cardiovascular/cerebrovascular disease or conditions predisposing to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (e.g., <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, use of antihypertensive medications) <span class="Italics">[see <a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">Dosage and Administration</a> (<a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">2.2</a>, <a href="#i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803">2.6</a>) and <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">Warnings and Precautions (5.3)</a>]. </span></span><br></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have occurred with clozapine treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering VERSACLOZ to patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or other predisposing risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (CNS pathology, medications that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>). Caution patients about engaging in any activity where sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious risk to themselves or others <span class="Italics">[see <a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">Dosage and Administration (2.2</a>) and <a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">Warnings and Precautions (5.4)</a>].</span></span><br></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></span></p>
<p><span class="Bold">Fatal <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> have occurred with clozapine treatment. Discontinue VERSACLOZ and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with VERSACLOZ-related <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> should not be rechallenged with VERSACLOZ. Consider the possibility of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> if <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or ECG changes occur <span class="Italics">[see <a href="#i4i_section_id_5fc47f63-7d6f-42d8-a4be-d26fe45faa0d">Warnings and Precautions (5.5)</a>].</span></span><br></p>
<p><span class="Bold"><span class="Underline">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></span></span></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. VERSACLOZ is not approved for use in patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#i4i_section_id_ace9148a-5bbd-492d-8a3b-0e65509e5451">Warnings and Precautions (5.6)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2da0cf99-f9d8-4817-8990-756eafe45a7c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1625a63b-95b1-41aa-8401-6369ec72dee7"></a><a name="section-1.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.1 Treatment-Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">VERSACLOZ is indicated for the treatment of severely ill patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> associated with its use, VERSACLOZ should be used only in patients who have failed to respond adequately to standard antipsychotic treatment <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1</a><span class="XmChange">, </span><a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">5.4</a><span class="XmChange">)]</span></span><span class="XmChange">.</span></p>
<p>The effectiveness of clozapine in treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine and chlorpromazine in patients who had failed other antipsychotics <span class="Italics">[see<a href="#i4i_section_id_1165a096-9a8b-42cb-a62f-f99ede2555d7"> Clinical Studies (14.1)]</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90d6c543-da97-4726-a898-6f6158490022"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Reduction in the Risk of Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorders</span></h2>
<p class="First">VERSACLOZ is indicated for reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span> who are judged to be at chronic risk for re-experiencing <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, based on history and recent clinical state. <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> refers to actions by a patient that put him/herself at risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>The effectiveness of clozapine in reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> was demonstrated over a two-year treatment period in the InterSePT™ trial <span class="Italics">[see <a href="#i4i_section_id_f390cb8d-d78a-45d1-9f52-9269e58c9d79">Clinical Studies (14.2)</a>]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c5a150cb-5bf1-4dfd-aae6-33dd75dc334d"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13a77ed2-fe7f-45d6-8e7c-eaefdea0caeb"></a><a name="section-2.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.1 Required Laboratory Testing Prior to Initiation and During Therapy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Prior to initiating treatment with VERSACLOZ, a baseline ANC must be obtained. The baseline ANC must be at least 1500/µL for the general population, and at least 1000/µL for patients with documented Benign Ethnic <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (BEN). To continue treatment, the ANC must be monitored regularly <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing Information  </h2>
<p class="First">The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages <span class="Italics">[see <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">Warnings and Precautions (5.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d03dec5d-446e-4f17-92f7-a1035c497719"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Important Administration Instructions  </h2>
<p class="First">VERSACLOZ Oral Suspension is administered to the mouth by the oral syringes provided (1 mL or 9 mL). After <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> the bottle for 10 seconds prior to each use, the syringe adaptor is pressed on top of the bottle. The oral syringe (1 mL or 9 mL) is filled with air, and inserted into the adaptor. The air is dispelled into the bottle and then the bottle is turned upside down. The prescribed amount of the suspension is drawn from the bottle and dispensed directly to the mouth. The prescribed dose should be administered immediately after it is prepared. Do not draw a dose and store it in the syringe for later use. After use, the oral syringe may be washed with warm water and dried for next use. The bottle may be closed with the same cap without removing the bottle adaptor. Educate patients and caregivers on the steps to administer VERSACLOZ as described in the Patient Instructions for Use.</p>
<p>VERSACLOZ can be taken with or without food <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537">Pharmacokinetics (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0fb3383-2fb2-440a-b148-59d7c8b6b7e9"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Maintenance Treatment</h2>
<p class="First">Generally, patients responding to VERSACLOZ should continue maintenance treatment on their effective dose beyond the acute episode.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b98d7c3d-1c53-4813-805b-05606f7f5289"></a><a name="section-2.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.5 Discontinuation of Treatment</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Method of treatment discontinuation will vary depending on the patient's last ANC:</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">See Tables 2 or 3 for appropriate ANC monitoring based on the level of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> if abrupt treatment discontinuation is necessary because of moderate to severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">Reduce the dose gradually over a period of 1 to 2 weeks if termination of VERSACLOZ therapy is planned and there is no evidence of moderate to severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">For abrupt clozapine discontinuation for a reason unrelated to <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥1500/µL and for BEN patients until their ANC is ≥1000/µL or above their baseline.</span></dd>
<dt>•</dt>
<dd>
<span class="XmChange">Additional ANC monitoring is required for any patient reporting onset of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (temperature of 38.5°C or 101.3°F, or greater) during the 2 weeks after discontinuation <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1)</a><span class="XmChange">]</span></span><span class="XmChange">.</span>
</dd>
<dt>•</dt>
<dd><span class="XmChange">Monitor all patients carefully for the recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms and symptoms related to cholinergic rebound such as profuse <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Re-Initiation of Treatment  </h2>
<p class="First">When restarting VERSACLOZ in patients who have discontinued VERSACLOZ (i.e., 2 days or more since the last dose), re-initiate with 12.5 mg once daily or twice daily. This is necessary to minimize the risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> <span class="Italics">[see <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">Warnings and Precautions (5.3)</a>]</span>. If that dose is well tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers  </h2>
<p class="First">Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John’s wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) <span class="Italics">[see <a href="#i4i_interactions_id_da25aa97-56f6-49bf-9c76-844d45424922">Drug Interactions (7)</a>]</span>. </p>
<p><span class="Bold">Table 1: Dose Adjustment in Patients Taking Concomitant Medications</span></p>
<table width="100%">
<col width="33%">
<col width="17%">
<col width="17%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Co-medications</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Scenarios</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Initiating VERSACLOZ while taking a co-medication</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Adding a co-medication while taking VERSACLOZ</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Discontinuing a co-medication while continuing VERSACLOZ</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Strong CYP1A2 Inhibitors</p></td>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">Use one third of the VERSACLOZ dose.</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Increase VERSACLOZ dose based on clinical response.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Moderate or Weak CYP1A2 Inhibitors</p></td>
<td class="Botrule Lrule Rrule" colspan="2" rowspan="2" valign="top"><p class="First">Monitor for adverse reactions. Consider reducing the VERSACLOZ dose if necessary.</p></td>
<td class="Botrule Lrule Rrule" rowspan="2" valign="top"><p class="First">Monitor for lack of effectiveness. Consider increasing VERSACLOZ dose if necessary.</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" valign="top"><p class="First">CYP2D6 or  CYP3A4 Inhibitors</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Strong CYP3A4 Inducers</p></td>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">Concomitant use is not recommended. However, if the inducer is necessary, it may be necessary to increase the VERSACLOZ dose. Monitor for decreased effectiveness.</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Reduce VERSACLOZ dose based on clinical response.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Moderate or weak CYP1A2 or CYP3A4 Inducers</p></td>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">Monitor for decreased effectiveness. Consider increasing the VERSACLOZ dose if necessary.</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Monitor for adverse reactions. Consider reducing the VERSACLOZ dose if necessary.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11b5b5bb-fbef-4d2d-a441-664325200ac8"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>, or CYP2D6 Poor Metabolizers</h2>
<p class="First">It may be necessary to reduce the VERSACLOZ dose in patients with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or in CYP2D6 poor metabolizers <span class="Italics">[see <a href="#i4i_section_id_702d3e1f-243a-4adb-ac7a-ef8fe37db74c">Use in Specific Populations (8.6</a>, <a href="#i4i_section_id_f4cd6b19-4bdf-4ac1-af7c-be6c02542777">8.7</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_8ce48dd6-b6ea-4bd7-8399-2fef322051e9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">VERSACLOZ is available as a free-flowing yellow oral suspension. Each mL contains 50 mg of clozapine.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c01c293b-9e50-4cfe-b969-df4e56f97cad"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb7d589a-ba4e-4c59-a274-42a834d32a03"></a><a name="section-4.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">VERSACLOZ is contraindicated in patients with a history of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clozapine (e.g., <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>) or any other component of VERSACLOZ <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#i4i_section_id_04611eab-3997-4b2e-a68d-5d6b6174afe2">Adverse Reactions (6.2)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_88053365-cf4c-4cf1-974b-dc9243e8bed8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Background</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">VERSACLOZ can cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (a low absolute neutrophil count [ANC]), defined as a reduction below pretreatment normal levels of <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">blood neutrophils</span>. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula: <span class="Italics">ANC equals the Total WBC count multiplied by the total percentage of <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> obtained from the differential (neutrophil “segs? plus neutrophil “bands?)</span>. Other granulocytes (<span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span> and eosinophils) contribute minimally to <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and their measurement is not necessary <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#i4i_section_id_04611eab-3997-4b2e-a68d-5d6b6174afe2">Adverse Reactions (6.2)</a><span class="XmChange">]</span></span><span class="XmChange">. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> may be mild, moderate, or severe (see Tables 2 and 3). To improve and standardize understanding, “severe neutropenia? replaces the previous terms severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, severe <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, ANC less than (&lt;) 500/µL, occurs in a small percentage of patients taking VERSACLOZ and is associated with an increase in the risk of serious and potentially fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Risk of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which VERSACLOZ causes <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is unknown and is not dose-dependent.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">VERSACLOZ Treatment and Monitoring in the General Patient Population (see Table 2)</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Obtain a CBC, including the ANC value, prior to initiating treatment with VERSACLOZ to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/µL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (≥) 1500/µL are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient's ANC remains equal to or greater than 1500/µL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 weeks for the next 6 months. If the ANC remains equal to or greater than 1500/µL for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to once every 4 weeks thereafter.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Table 2: VERSACLOZ Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring for the General Patient Population</span></span></p>
<table width="100%">
<col width="21%">
<col width="41%">
<col width="38%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ANC Level</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">VERSACLOZ</span><br><span class="Bold">Treatment Recommendations</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ANC Monitoring</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Normal range</span><br><span class="Bold">(≥1500/µL)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt>•</dt>
<dd>Initiate treatment</dd>
<dt>•</dt>
<dd>If treatment interrupted:<dl>
<dt>•</dt>
<dd>&lt;30 days, continue monitoring as before</dd>
<dt>•</dt>
<dd>≥30 days, monitor as if new patient</dd>
</dl>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt>•</dt>
<dd>Weekly from initiation to 6 months</dd>
<dt>•</dt>
<dd>Every 2 weeks from 6 to 12 months</dd>
<dt>•</dt>
<dd>Monthly after 12 months</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Discontinuation for reasons other than <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>See Section 2.4</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Mild <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (1000 to 1499/µL)*</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Continue treatment</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Three times weekly until ANC ≥1500/µL</dd>
<dt>•</dt>
<dd>Once ANC ≥1500/µL, return to patient's last “Normal Range? ANC monitoring interval**</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Moderate <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (500 to 999/µL)*</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Recommend hematology consultation</dd>
<dt>•</dt>
<dd>Interrupt treatment for suspected clozapine-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
<dt>•</dt>
<dd>Resume treatment once ANC ≥1000/µL</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Daily until ANC ≥1000/µL, then</dd>
<dt>•</dt>
<dd>Three times weekly until ANC ≥1500/µL</dd>
<dt>•</dt>
<dd>Once ANC ≥1500/µL, check ANC weekly for 4 weeks, then return to patient's last “Normal Range? ANC monitoring interval**</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (less than 500/µL)*</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Recommend hematology consultation</dd>
<dt>•</dt>
<dd>Interrupt treatment for suspected clozapine-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
<dt>•</dt>
<dd>Do not rechallenge unless prescriber determines benefits outweigh risks</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Daily until ANC ≥1000/µL, then</dd>
<dt>•</dt>
<dd>Three times weekly until ANC ≥1500/µL</dd>
<dt>•</dt>
<dd>If patient rechallenged, resume treatment as a new patient under “Normal Range? monitoring once ANC ≥1500/µL</dd>
</dl></td>
</tr>
</tbody>
</table>
<p>*   Confirm all <span class="Underline">initial</span> reports of ANC less than 1500/µL with a repeat ANC measurement within 24 hours<br>** If clinically appropriate</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">VERSACLOZ Treatment and Monitoring in Patients with Benign Ethnic <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (see Table 3)</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Benign ethnic <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (BEN) is a condition observed in certain ethnic groups whose average ANC values are lower than “standard? laboratory ranges for <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>. It is most commonly observed in individuals of African descent (approximate prevalence of 25-50%), some Middle Eastern ethnic groups, and in other non-Caucasian ethnic groups with darker skin. BEN is more common in men. Patients with BEN have normal hematopoietic stem-cell number and myeloid maturation, are healthy, and do not suffer from repeated or severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. They are not at increased risk for developing VERSACLOZ-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Additional evaluation may be needed to determine if baseline <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is due to BEN. Consider hematology consultation before initiating or during VERSACLOZ treatment as necessary.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients with BEN require a different ANC algorithm for VERSACLOZ management due to their lower baseline ANC levels. Table 3 provides guidelines for managing VERSACLOZ treatment and ANC monitoring in patients with BEN.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Table 3: Patients with Benign Ethnic <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (BEN); VERSACLOZ Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring</span></span></p>
<table width="100%">
<col width="21%">
<col width="41%">
<col width="38%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ANC Level</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Treatment Recommendations</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">ANC Monitoring</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Normal BEN Range</span><br><span class="Bold">(Established ANC baseline ≥1000/µL)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<dl>
<dt> </dt>
<dd>•Obtain at least two baseline ANC levels before initiating treatment</dd>
<dt> </dt>
<dd>•If treatment interrupted:</dd>
</dl>
<dl>
<dt>•</dt>
<dd>&lt;30 days, continue monitoring as before</dd>
<dt>•</dt>
<dd>≥30 days, monitor as if new patient</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>•Weekly from initiation to 6 months</dd>
<dt> </dt>
<dd>•Every 2 weeks from 6 to 12 months</dd>
<dt> </dt>
<dd>•Monthly after 12 months</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>•Discontinuation of treatment for reasons other than <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>•See Section 2.4</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">BEN <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (500 to 999/µL)*</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>•Recommend hematology consultation</dd>
<dt> </dt>
<dd>•Continue treatment</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>•Three times weekly until ANC ≥1000/µL or ≥patient's known baseline</dd>
<dt> </dt>
<dd>•Once ANC ≥1000/µL or at patient's known baseline, check ANC weekly for 4 weeks, then return to patient's last “Normal BEN Range? ANC monitoring interval**</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">BEN</span><br><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (less than 500/µL)*</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>•Recommend hematology consultation</dd>
<dt> </dt>
<dd>•Interrupt treatment for suspected clozapine-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
<dt> </dt>
<dd>•Do not rechallenge unless prescriber determines benefits outweigh risks</dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>•Daily until ANC ≥500/µL, then</dd>
<dt> </dt>
<dd>•Three times weekly until ANC ≥patient's baseline</dd>
<dt> </dt>
<dd>•If patient rechallenged, resume treatment as a new patient under “Normal Range? monitoring once ANC ≥1000/µL or at patient's baseline</dd>
</dl></td>
</tr>
</tbody>
</table>
<p>*   Confirm all initial reports of ANC less than 1500/µL with a repeat ANC measurement within 24 hours<br>** If clinically appropriate</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">General Guidelines for Management of All Patients with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></span></span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>: Interrupt VERSACLOZ as a precautionary measure in any patient who develops <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, defined as a temperature of 38.5°C [101.3°F] or greater, and obtain an ANC level. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> is often the first sign of neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">ANC less than 1000/µL: If <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> occurs in any patient with an ANC less than 1000/µL, initiate appropriate workup and treatment for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and refer to Tables 2 or 3 for management.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">Consider hematology consultation.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">See <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> under WARNINGS AND PRECAUTIONS (5) and Instructions for Patients, under PATIENT COUNSELING INFORMATION (17).</span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Rechallenge after an ANC less than 500/µL (severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>)</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">For some patients who experience severe VERSACLOZ-related <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, the risk of serious psychiatric illness from discontinuing VERSACLOZ treatment may be greater than the risk of rechallenge (e.g., patients with severe schizophrenic illness who have no treatment options other than VERSACLOZ). A hematology consultation may be useful in deciding to rechallenge a patient. In general, however, do not rechallenge patients who develop severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> with VERSACLOZ or a clozapine product.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">If a patient will be rechallenged, the clinician should consider thresholds provided in Tables 2 and 3, the patient's medical and psychiatric history, a discussion with the patient and his/her caregiver about the benefits and risks of VERSACLOZ rechallenge, and the severity and characteristics of the neutropenic episode.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Using VERSACLOZ with Other Drugs Associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">It is unclear if concurrent use of other drugs known to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> increases the risk or severity of VERSACLOZ-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. There is no strong scientific rationale to avoid VERSACLOZ treatment in patients concurrently treated with these drugs. If VERSACLOZ is used concurrently with an agent known to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (e.g., some chemotherapeutic agents), consider monitoring patients more closely than the treatment guidelines provided in Tables 2 and 3. Consult with the treating oncologist in patients receiving concomitant chemotherapy.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4521df88-52ae-4448-aa3c-eec77b0f7e13"></a><a name="section-5.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.2 Clozapine REMS Program</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">VERSACLOZ is only available through a restricted program under a REMS called the Clozapine REMS Program because of the risk of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Notable requirements of the Clozapine REMS Program include:</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">Healthcare professionals who prescribe VERSACLOZ must be certified with the program by enrolling and completing training.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">Patients who receive VERSACLOZ must be enrolled in the program and comply with the ANC testing and monitoring requirements.</span></dd>
<dt>•</dt>
<dd><span class="XmChange">Pharmacies dispensing VERSACLOZ must be certified with the program by enrolling and completing training and must only dispense to patients who are eligible to receive VERSACLOZ.</span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange">Further information is available at </span><a href="http://www.clozapinerems.com">www.clozapinerems.com</a><span class="XmChange"> or 1-844-267-8678.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally mediated <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">reflex bradycardia</span> (NMRB).</p>
<p>Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions <span class="Italics">[see <a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">Dosage and Administration (2.2)</a>]</span>. Consider reducing the dose if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs. When restarting patients who have had even a brief interval off VERSACLOZ (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily <span class="Italics">[see <a href="#i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803">Dosage and Administration (2.6)</a>].</span></p>
<p>Use VERSACLOZ cautiously in patients with cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (e.g., concomitant use of antihypertensives, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> has been estimated to occur in association with clozapine use at a cumulative incidence at one year of approximately 5%, based on the occurrence of one or more <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in 61 of 1743 patients exposed to clozapine during its clinical testing prior to domestic marketing (i.e., a crude rate of 3.5%). The risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> is dose-related. Initiate treatment with a low dose (12.5 mg), titrate slowly, and use divided dosing. </p>
<p>Use caution when administering VERSACLOZ to patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or other predisposing risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (e.g., head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or other CNS pathology, use of medications that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>). Because of the substantial risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> associated with VERSACLOZ use, caution patients about engaging in any activity where sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious risk to themselves or others (e.g., driving an automobile, operating complex machinery, swimming, climbing).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5fc47f63-7d6f-42d8-a4be-d26fe45faa0d"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> have occurred with the use of clozapine. These reactions can be fatal. Discontinue VERSACLOZ and obtain a cardiac evaluation upon suspicion of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. Generally, patients with a history of clozapine-associated <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> should not be rechallenged with VERSACLOZ. However, if the benefit of VERSACLOZ treatment is judged to outweigh the potential risks of recurrent <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, the clinician may consider rechallenge with VERSACLOZ in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.</p>
<p>Consider the possibility of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> or <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> in patients receiving VERSACLOZ who present with <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, persistent <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> at rest, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like symptoms, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, other signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or electrocardiographic findings (low voltages, ST-T abnormalities, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, right axis deviation, and poor R wave progression). <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> most frequently presents within the first two months of clozapine treatment. Symptoms of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> generally occur later than clozapine-associated <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and usually after 8 weeks of treatment. However, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> can occur at any period during treatment with VERSACLOZ. It is common for nonspecific flu-like symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, pleuritic <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and low-grade <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> to precede more overt signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Typical laboratory findings include elevated <span class="product-label-link" type="condition" conceptid="4010039" conceptname="Troponin I">troponin I</span> or T, elevated creatinine kinase-MB, peripheral <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and elevated C-reactive protein (CRP). Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionucleotide studies, or cardiac catheterization) may reveal evidence of <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ace9148a-5bbd-492d-8a3b-0e65509e5451"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in this population. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. VERSACLOZ is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#_Ref">Boxed Warning</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39fa211a-87d7-4869-90ff-2b053c9f4fe7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, defined as a blood eosinophil count of greater than 700/μL, has occurred with clozapine treatment. In clinical trials, approximately 1% of patients developed <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. Clozapine-related <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> usually occurs during the first month of treatment. In some patients, it has been associated with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, and <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. Such organ involvement could be consistent with a drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms syndrome (DRESS), also known as drug induced <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> (DIHS). If <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> develops during VERSACLOZ treatment, evaluate promptly for signs and symptoms of systemic reactions, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other allergic symptoms, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, or other organ-specific disease associated with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. If clozapine-related systemic disease is suspected, discontinue VERSACLOZ immediately. </p>
<p>If a cause of <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> unrelated to clozapine is identified (e.g., <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, allergies, collagen vascular disease, parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and specific neoplasms), treat the underlying cause and continue VERSACLOZ. </p>
<p>Clozapine-related <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> has also occurred in the absence of organ involvement and can resolve without intervention. There are reports of successful rechallenge after discontinuation of clozapine, without recurrence of <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. In the absence of organ involvement, continue VERSACLOZ under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt VERSACLOZ therapy and rechallenge after the eosinophil count decreases should be based on the overall clinical assessment, in consultation with an internist or hematologist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2abb5581-d2b8-4aa2-b803-4e5cf73a4e7b"></a><a name="section-5.8"></a><p></p>
<h2>5.8 QT Interval Prolongation</h2>
<p class="First">QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> and other life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> have occurred with clozapine treatment. When prescribing VERSACLOZ, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, family history of <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> or <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span>, significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of VERSACLOZ, and electrolyte abnormalities. </p>
<p>Prior to initiating treatment with VERSACLOZ, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue VERSACLOZ if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span> or other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, (e.g., <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>), obtain a cardiac evaluation and discontinue VERSACLOZ. </p>
<p>Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of VERSACLOZ. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmic (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). VERSACLOZ is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of VERSACLOZ <span class="Italics">[see <a href="#i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb">Drug Interactions (7.1)</a> and <a href="#i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537"> Clinical Pharmacology (12.3)</a>].</span></p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> increase the risk of QT prolongation. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can result from diuretic therapy, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and other causes. Use caution when treating patients at risk for significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbance</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with VERSACLOZ. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Metabolic Changes</h2>
<p class="First">Atypical antipsychotic drugs, including VERSACLOZ, have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics including VERSACLOZ. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with atypical antipsychotics are not available.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on VERSACLOZ should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.</p>
<p>In a pooled data analysis of 8 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the mean changes in fasting glucose concentration in the clozapine and chlorpromazine groups were +11 mg/dL and +4 mg/dL respectively. A higher proportion of the clozapine group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 4). The clozapine doses were 100-900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for clozapine and chlorpromazine.</p>
<p><span class="Bold">Table 4: Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<table width="100%">
<col width="15%">
<col width="21%">
<col width="21%">
<col width="21%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Laboratory Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Category Change (at least once) from baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="4" valign="top"><p class="First">Fasting Glucose</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Normal </p>
<p>(&lt;100 mg/dL)</p>
<p>to</p>
<p>High (≥126 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">198</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">53 (27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">135</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14 (10)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Borderline </p>
<p>(100 to 125 mg/dL)</p>
<p>to</p>
<p>High (≥126 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">57</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">24 (42)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">43</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12 (28)</p></td>
</tr>
</tbody>
</table>
<p> <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></span></p>
<p>Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including VERSACLOZ. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using VERSACLOZ, is recommended.</p>
<p>In a pooled data analysis of 10 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, clozapine treatment was associated with increases in serum total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. No data were collected on LDL and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. The mean increase in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 13 mg/dL in the clozapine group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, clozapine treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the clozapine group and 39 mg/dL (35%) in the chlorpromazine group (Table 5). In addition, clozapine treatment was associated with categorical increases in serum total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride, as illustrated in Table 6. The proportion of patients with categorical increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or fasting triglyceride increased with the duration of exposure. The median duration of clozapine and chlorpromazine exposure was 45 days and 38 days, respectively. The clozapine dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily. </p>
<p><span class="Bold">Table 5: Mean Changes in Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and Triglyceride Concentration in Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<table width="100%">
<col width="28%">
<col width="39%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Baseline total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Change from baseline mg/dL (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine (N=334)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">184</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">+13 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine (N=185)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">182</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">+15 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Baseline triglyceride concentration (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Change from baseline mg/dL (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine (N=6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">130</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">+71 (54)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine (N=7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">110</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">+39 (35)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 6: Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<table width="100%">
<col width="15%">
<col width="21%">
<col width="21%">
<col width="21%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Laboratory Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Category Change (at least once) from Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="6" valign="top">
<p class="First">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></p>
<p>(random or fasting)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Increase by ≥40 </p>
<p>mg/dL</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">334</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">111 (33)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">185</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">46 (25)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Normal (&lt;200 mg/dL) </p>
<p>to</p>
<p>High (≥240 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">222</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">132</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Borderline </p>
<p>(200 - 239 mg/dL) to</p>
<p>High (≥240 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30 (38)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14 (41)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="6" valign="top">
<p class="First">Triglycerides</p>
<p>(fasting)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Increase by ≥50 mg/dL</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (50)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (43)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Normal (&lt;150 mg/dL) </p>
<p>to</p>
<p>High (≥200 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2 (33)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Borderline </p>
<p>(≥150 mg/dL and </p>
<p>&lt;200 mg/dL) to</p>
<p>High (≥200 mg/dL)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clozapine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (100)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chlorpromazine</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0 (0)</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has occurred with the use of antipsychotics, including VERSACLOZ. Monitor weight during treatment with VERSACLOZ. Table 7 summarizes the data on <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> by the duration of exposure pooled from 11 studies with clozapine and active comparators. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.</p>
<p><span class="Bold">Table 7: Mean Change in Body Weight (kg) by duration of exposure from studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span></span></p>
<table width="100%">
<col width="12%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="12%">
<col width="12%">
<col width="11%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Metabolic parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Exposure duration</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Clozapine</span></p>
<p><span class="Bold">(N=669)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<p><span class="Bold">(N=442)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Chlorpromazine</span></p>
<p><span class="Bold">(N=155)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Mean</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Mean</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Mean</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="6" valign="top"><p class="First"><span class="Bold">Weight change from baseline</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 weeks (Day 11 – 17)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+0.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+0.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4 weeks (Day 21 – 35)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">23</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+0.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+0.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8 weeks (Day 49 – 63)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+1.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+0.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12 weeks (Day 70 – 98)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+2.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+3.1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">24 weeks (154 – 182)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-0.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+5.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">48 weeks (Day 322 – 350)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+3.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+13.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>Table 8 summarizes pooled data from 11 studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> demonstrating <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> ≥7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.</p>
<p><span class="Bold">Table 8: Proportion of adult subjects in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> studies with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> ≥7% relative to baseline body weight</span></p>
<table width="100%">
<col width="29%">
<col width="23%">
<col width="24%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Weight change</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Clozapine</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Olanzapine</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Chlorpromazine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">669</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">442</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">155</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">≥7% (inclusive)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">236 (35%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">203 (46%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13 (8%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18276b32-9318-48bf-b5b5-2141660e9fca"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">Antipsychotic drugs including VERSACLOZ can cause a potentially fatal symptom complex referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS). Clinical manifestations of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>). Associated findings can include elevated creatine phosphokinase (CPK), <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, primary CNS pathology, central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>).</p>
<p>The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of co-morbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.</p>
<p>NMS has occurred with clozapine monotherapy and with concomitant CNS-active medications, including lithium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_875c48ff-3ac3-4a1b-9d62-5149b804f87a"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First">During clozapine therapy, patients have experienced transient, clozapine-related <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The peak incidence is within the first 3 weeks of treatment. While this <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> is generally benign and self-limited, it may necessitate discontinuing treatment. The <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> can be associated with an increase or decrease in WBC count. Carefully evaluate patients with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> to rule out severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Consider the possibility of NMS <span class="Italics">[see <a href="#i4i_section_id_18276b32-9318-48bf-b5b5-2141660e9fca">Warnings and Precautions (5.10)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2cbc7301-c238-482c-9a0d-460b6ad982ef"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> have occurred in patients treated with clozapine. Consider the possibility of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> in patients who present with deep vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">acute dyspnea</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or with other respiratory signs and symptoms. Whether <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> can be attributed to clozapine or some characteristic(s) of patients is not clear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0986f3d4-d5d4-45d4-b38f-dffbf4cb2c26"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Anticholinergic Toxicity</h2>
<p class="First">VERSACLOZ has potent anticholinergic effects. Treatment with VERSACLOZ can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, concomitant anticholinergic medications, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or other conditions in which anticholinergic effects can lead to significant adverse reactions. </p>
<p>Treatment with VERSACLOZ can result in gastrointestinal adverse reactions, including <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, and <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. Such reactions can be fatal. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f1218f8-ee95-41e3-9999-64e3a0d73782"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Interference with Cognitive and Motor Performance</h2>
<p class="First">VERSACLOZ can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that VERSACLOZ does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfc6241a-e8c1-45c3-84c7-7daed7531716"></a><a name="section-5.15"></a><p></p>
<h2>5.15 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> (TD) has occurred in patients treated with antipsychotic drugs, including VERSACLOZ. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe VERSACLOZ in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with VERSACLOZ despite the presence of the syndrome.</p>
<p>There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ea4ad11-fe06-4f86-999c-433fad73f13e"></a><a name="section-5.16"></a><p></p>
<h2> 5.16 Cerebrovascular Adverse Reactions </h2>
<p class="First">In controlled trials, elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for VERSACLOZ or other antipsychotics or other patient populations. VERSACLOZ should be used with caution in patients with risk factors for cerebrovascular adverse reactions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1ad69e4d-ccc7-4fb3-b655-12376373b958"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> and Cholinergic Rebound after Abrupt Discontinuation of VERSACLOZ</h2>
<p class="First">If abrupt discontinuation of VERSACLOZ is necessary (because of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or another medical condition, for example) <span class="Italics">[see <a href="#i4i_section_id_b98d7c3d-1c53-4813-805b-05606f7f5289">Dosage and Administration (2.5)</a>, <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1)</a>]</span>, monitor carefully for the recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms and adverse reactions related to cholinergic rebound, such as profuse <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b5e9709f-f2bd-4f5e-8127-ffcba6435be9"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<dl>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> <span class="Italics">[see <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> <span class="Italics">[see <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">Warnings and Precautions (5.3)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see <a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">Warnings and Precautions (5.4)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> <span class="Italics">[see <a href="#i4i_section_id_5fc47f63-7d6f-42d8-a4be-d26fe45faa0d">Warnings and Precautions (5.5)</a>].</span>
</dd>
<dt>•</dt>
<dd>Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> <span class="Italics">[see <a href="#i4i_section_id_ace9148a-5bbd-492d-8a3b-0e65509e5451">Warnings and Precautions (5.6)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> <span class="Italics">[see <a href="#i4i_section_id_39fa211a-87d7-4869-90ff-2b053c9f4fe7">Warnings and Precautions (5.7)</a>].</span>
</dd>
<dt>•</dt>
<dd>QT Interval Prolongation <span class="Italics">[see <a href="#i4i_section_id_2abb5581-d2b8-4aa2-b803-4e5cf73a4e7b">Warnings and Precautions (5.8)</a>].</span>
</dd>
<dt>•</dt>
<dd>Metabolic Changes (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>)<span class="Italics"> [see <a href="#i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46">Warnings and Precautions (5.9)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> <span class="Italics">[see <a href="#i4i_section_id_18276b32-9318-48bf-b5b5-2141660e9fca">Warnings and Precautions (5.10)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> <span class="Italics">[see <a href="#i4i_section_id_875c48ff-3ac3-4a1b-9d62-5149b804f87a">Warnings and Precautions (5.11)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> <span class="Italics">[see <a href="#i4i_section_id_2cbc7301-c238-482c-9a0d-460b6ad982ef">Warnings and Precautions (5.12)</a>].</span>
</dd>
<dt>•</dt>
<dd>Anticholinergic Toxicity <span class="Italics">[see <a href="#i4i_section_id_0986f3d4-d5d4-45d4-b38f-dffbf4cb2c26">Warnings and Precautions (5.13)</a>].</span>
</dd>
<dt>•</dt>
<dd>Interference with Cognitive and Motor Performance <span class="Italics">[see <a href="#i4i_section_id_5f1218f8-ee95-41e3-9999-64e3a0d73782">Warnings and Precautions (5.14)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> <span class="Italics">[see <a href="#i4i_section_id_bfc6241a-e8c1-45c3-84c7-7daed7531716">Warnings and Precautions (5.15)</a>].</span>
</dd>
<dt>•</dt>
<dd>Cerebrovascular Adverse Reactions <span class="Italics">[see<a href="#i4i_section_id_2ea4ad11-fe06-4f86-999c-433fad73f13e"> Warnings and Precautions (5.16)</a>].</span>
</dd>
<dt>•</dt>
<dd>Recurrence of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> and Cholinergic Rebound after Abrupt Discontinuation<span class="Italics"> [see <a href="#i4i_section_id_1ad69e4d-ccc7-4fb3-b655-12376373b958">Warnings and Precautions (5.17)</a>].</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d19c6d4-4f3c-4194-b978-a8cfcf33690c"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most commonly reported adverse reactions (<span class="Underline">&gt;</span>5%) across clozapine clinical trials were: CNS reactions, including sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>; cardiovascular reactions, including <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; autonomic nervous system reactions, including <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; gastrointestinal reactions, including <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Table 9 summarizes the most commonly reported adverse reactions (<span class="Underline">&gt;</span>5%) in clozapine-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<p><span class="Bold">Table 9: Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<table width="100%">
<col width="40%">
<col width="29%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Clozapine</span></p>
<p><span class="Bold">(N=126)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Chlorpromazine</span></p>
<p><span class="Bold">(N=142)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Sedation</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (<span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>)</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Hypersalivation</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">21</p>
<p>17</p>
<p>16</p>
<p>14</p>
<p>13</p>
<p>13</p>
<p>13</p>
<p>12</p>
<p>10</p>
<p>10</p>
<p>5</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">13</p>
<p>11</p>
<p>12</p>
<p>16</p>
<p>38</p>
<p>4</p>
<p>1</p>
<p>5</p>
<p>10</p>
<p>12</p>
<p>20</p>
</td>
</tr>
</tbody>
</table>
<p>Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all clozapine studies (excluding the 2-year InterSePT<span class="Sup">™</span> Study). These rates are not adjusted for duration of exposure.</p>
<p><span class="Bold">Table 10: Adverse Reactions (≥2%) Reported in Clozapine-treated Patients (N=842) across all Clozapine Studies (excluding the 2-year InterSePT™ Study) </span></p>
<table width="100%">
<col width="57%">
<col width="43%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Body System</span><br><span class="Bold">     Adverse Reaction</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Clozapine</span></p>
<p><span class="Bold">N=842</span><br><span class="Bold">Percentage of Patients</span></p>
</td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Central Nervous System</span><br>     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>/Sedation <br>     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span><br>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>39<br>19<br>7<br>6</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span><br>     Disturbed Sleep/<span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmares</span><br>     <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span><br>     <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span>/<span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">Akinesia</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6<br>4<br>4<br>4</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span><br>     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>)<br>     <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Rigidity</span><br>     <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><br>     <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span><br>     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Rrule" align="center" valign="top">
<p class="First">4<br> 3†<br>3<br>3<br>3<br>2</p>
<p>2</p>
</td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Cardiovascular</span><br>     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span><br>     <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><br>     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>25†<br>9<br>4</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Gastrointestinal</span><br>     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>     <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span>/<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span><br>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>14<br>5<br>4<br>3<br>3<br>2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Urogenital</span><br>     Urinary Abnormalities</p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Autonomic Nervous System</span><br>     <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivation</span><br>     <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span><br>     <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br>     <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbances</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>31<br>6<br>6<br>5</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Skin</span><br>     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>2</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Hemic/Lymphatic</span><br>     <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/Decreased WBC/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </p></td>
<td class="Rrule" align="center" valign="top"><p class="First">3<br></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Miscellaneous</span><br>     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>     <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span><br></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><br>5<br>4<br></p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="2" valign="top"><dl>
<dt> </dt>
<dd>†	Rate based on population of approximately 1700 exposed during premarket clinical evaluation of clozapine.</dd>
</dl></td></tr>
</tbody>
</table>
<p>Table 11 summarizes the most commonly reported adverse reactions (<span class="Underline">&gt;</span>10% of the clozapine or olanzapine group) in the InterSePT<span class="Sup">™ </span>Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of clozapine relative to olanzapine in reducing the risk of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>. The rates are not adjusted for duration of exposure.</p>
<p><span class="Bold">Table 11: Incidence of Adverse Reactions in Patients Treated with Clozapine or Olanzapine in the InterSePT™ Study (≥10% in the clozapine or olanzapine group)</span></p>
<table width="100%">
<col width="45%">
<col width="22%">
<col width="34%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Reactions</span></p></td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Clozapine</span></p>
<p><span class="Bold">N=479</span></p>
<p><span class="Bold">% Reporting</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Olanzapine</span></p>
<p><span class="Bold">N=477</span></p>
<p><span class="Bold">% Reporting</span></p>
</td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></p></td>
<td align="center" valign="top"><p class="First">48%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td align="center" valign="top"><p class="First">46%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">25%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></p></td>
<td align="center" valign="top"><p class="First">31%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">56%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</p></td>
<td align="center" valign="top"><p class="First">27%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td align="center" valign="top"><p class="First">25%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td align="center" valign="top"><p class="First">20%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">33%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="top"><p class="First">17%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td align="center" valign="top"><p class="First">17%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">9%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">14%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></span></span></p>
<p><span class="Italics">Class effect:</span> Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04611eab-3997-4b2e-a68d-5d6b6174afe2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of clozapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="Underline">Central Nervous System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">Delirium</span>, <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">EEG abnormal</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, possible <span class="product-label-link" type="condition" conceptid="4263753" conceptname="Cataplexy">cataplexy</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions.</p>
<p><span class="Italics"><span class="Underline">Cardiovascular System</span></span></p>
<p>Atrial or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, QT interval prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de Pointes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>.</p>
<p><span class="Italics"><span class="Underline">Endocrine System</span></span></p>
<p>Pseudopheochromocytoma.</p>
<p><span class="Italics"><span class="Underline">Gastrointestinal System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="28461" conceptname="Hypertrophy of salivary gland">salivary gland swelling</span>.</p>
<p><span class="Italics"><span class="Underline">Hepatobiliary System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">Cholestasis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (hepatic, cholestatic, and mixed), and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>.</p>
<p><span class="Italics"><span class="Underline">Urogenital System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">Acute interstitial nephritis</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><span class="Italics"><span class="Underline">Skin and Subcutaneous Tissue Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span> disorder, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>.</p>
<p><span class="Italics"><span class="Underline">Musculoskeletal System and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">Myasthenic syndrome</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p><span class="Italics"><span class="Underline">Respiratory System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">Aspiration</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>.</p>
<p><span class="Italics"><span class="Underline">Hemic and Lymphatic System</span></span></p>
<p>Mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, WBC decreased, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, elevated hemoglobin/hematocrit, <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span> (ESR) increased, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics"><span class="Underline">Vision Disorders</span></span></p>
<p>Narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p><span class="Italics"><span class="Underline">Miscellaneous</span></span></p>
<p>Creatine phosphokinase elevation, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_da25aa97-56f6-49bf-9c76-844d45424922"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential for Other Drugs to Affect VERSACLOZ</h2>
<p class="First">Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering VERSACLOZ concomitantly with drugs that are inducers or inhibitors of these enzymes.</p>
<p><span class="Italics"><span class="Underline">CYP1A2 Inhibitors</span></span></p>
<p>Concomitant use of VERSACLOZ and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the VERSACLOZ dose to one third of the original dose when VERSACLOZ is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The VERSACLOZ dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued <span class="Italics">[see <a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">Dosage and Administration (2.7)</a>, <a href="#i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537">Clinical Pharmacology (12.3)</a>].</span></p>
<p>Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when VERSACLOZ is coadministered with these inhibitors. Consider reducing the VERSACLOZ dosage if necessary <span class="Italics">[see <a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">Dosage and Administration (2.7)</a>]</span>. </p>
<p><span class="Italics"><span class="Underline">CYP2D6 and CYP3A4 Inhibitors</span></span></p>
<p>Concomitant treatment with VERSACLOZ and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537">Clinical Pharmacology (12.3)</a>]</span>. Use caution and monitor patients closely when using such inhibitors. Consider reducing the VERSACLOZ dose <span class="Italics">[see <a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">Dosage and Administration (2.7)</a>]</span>. </p>
<p><span class="Italics"><span class="Underline">CYP1A2 and CYP3A4 Inducers</span></span></p>
<p>Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of VERSACLOZ. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John’s wort, and rifampin. It may be necessary to increase the VERSACLOZ dose if used concomitantly with inducers of these enzymes. However, concomitant use of VERSACLOZ and strong CYP3A4 inducers is not recommended <span class="Italics">[see <a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">Dosage and Administration (2.7)</a>].</span></p>
<p>Consider reducing the VERSACLOZ dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions <span class="Italics">[see <a href="#i4i_section_id_75d81272-828a-4575-83ab-debd499af0d7">Dosage and Administration (2.7)</a>].</span></p>
<p><span class="Italics"><span class="Underline">Drugs that Cause QT Interval Prolongation </span></span></p>
<p>Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of VERSACLOZ. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) <span class="Italics">[see <a href="#i4i_section_id_2abb5581-d2b8-4aa2-b803-4e5cf73a4e7b">Warnings and Precautions (5.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3145fa55-4794-4c9d-87cb-d0c5d14e9660"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for VERSACLOZ to Affect Other Drugs</h2>
<p class="First">Concomitant use of VERSACLOZ with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering VERSACLOZ with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_1f9db068-31e9-4c0a-84f1-1f794b3b793d"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8a7bad36-b81d-4c50-a11d-401fa6ee090c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B</p>
<p><span class="Underline">Risk Summary</span></p>
<p>There are no adequate or well-controlled studies of clozapine in pregnant women. </p>
<p>Reproduction studies have been performed in rats and rabbits at doses up to 0.4 and 0.9 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m<span class="Sup">2</span> body surface area basis. The studies revealed no evidence of impaired fertility or harm to the fetus due to clozapine. Because animal reproduction studies are not always predictive of human response, VERSACLOZ should be used during pregnancy only if clearly needed.</p>
<p><span class="Underline">Clinical Considerations</span></p>
<p>Consider the risk of exacerbation of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> when discontinuing or changing treatment with antipsychotic medications during pregnancy and postpartum. Consider early screening for <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> for patients treated with antipsychotic medications <span class="Italics">[see <a href="#i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46">Warnings and Precautions (5.9)</a>]. </span>Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, and feeding difficulties. The severity of complications can vary from self-limited symptoms to some neonates requiring intensive care unit support and prolonged hospitalization.</p>
<p><span class="Underline">Animal Data</span></p>
<p>In embryofetal developmental studies, clozapine had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m<span class="Sup">2</span> body surface area basis.</p>
<p>In peri/postnatal developmental studies, pregnant female rats were administered clozapine over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Clozapine caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m<span class="Sup">2</span> body surface area basis.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_cdbdf840-e375-478d-9926-daa624f42b98"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">VERSACLOZ is present in human milk. Because of the potential for serious adverse reactions in nursing infants from VERSACLOZ, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_0a6c10df-e043-4318-96cd-1ea97fd082f5"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_fad2f9f8-4c59-4480-96a9-d9652e5a8fca"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric patients in clinical studies utilizing VERSACLOZ to determine whether those over 65 years of age differ from younger subjects in their response to VERSACLOZ.</p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> can occur with clozapine treatment <span class="Italics">[see <a href="#_Ref">Boxed Warning</a> and <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">Warnings and Precautions (5.3)</a>].</span> Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects.</p>
<p>Elderly patients may be particularly susceptible to the anticholinergic effects of clozapine, such as <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> <span class="Italics">[see<a href="#i4i_section_id_0986f3d4-d5d4-45d4-b38f-dffbf4cb2c26"> Warnings and Precautions (5.13)</a>].</span></p>
<p>Carefully select VERSACLOZ doses in elderly patients, taking into consideration their greater frequency of decreased hepatic, renal, or cardiac function, as well as other concomitant disease and other drug therapy. Clinical experience suggests that the prevalence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appears to be highest among the elderly; especially elderly women <span class="Italics">[see <a href="#i4i_section_id_bfc6241a-e8c1-45c3-84c7-7daed7531716">Warnings and Precautions (5.15)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_702d3e1f-243a-4adb-ac7a-ef8fe37db74c"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted <span class="Italics">[see <a href="#i4i_section_id_11b5b5bb-fbef-4d2d-a441-664325200ac8">Dosage and Administration (2.8)</a>, <a href="#i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f4cd6b19-4bdf-4ac1-af7c-be6c02542777"></a><a name="section-8.6"></a><p></p>
<h2>8.7 CYP2D6 Poor Metabolizers</h2>
<p class="First">Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted <span class="Italics">[see<a href="#i4i_section_id_11b5b5bb-fbef-4d2d-a441-664325200ac8"> Dosage and Administration (2.8)</a>, <a href="#i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7f5865ec-14a4-4c73-aa39-0a8a821c6eaf"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Hospice Patients </h2>
<p class="First">For hospice patients (i.e., terminally ill patients with an estimated life expectancy of 6 months or less), the prescriber may reduce the ANC monitoring frequency to once every 6 months, after a discussion with the patient and his/her caregiver. Individual treatment decisions should weigh the importance of monitoring ANC in the context of the need to control <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> and the patient's terminal illness.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_441a785a-704c-499c-baae-90a333920f42"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4ed756a-979b-4b61-8874-d42f865b4bd9"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Overdosage Experience</h2>
<p class="First">The most commonly reported signs and symptoms associated with clozapine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are: sedation, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or failure, and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>. There are reports of <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been reported with clozapine, generally at doses above 2500 mg. There have also been reports of patients recovering from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> well in excess of 4 g.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eba1315a-0ca3-495c-92e2-4ed692a678c7"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Management of Overdosage</h2>
<p class="First">For the most up-to-date information on the management of VERSACLOZ overdosage, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the <span class="Italics">Physicians’ Desk Reference<span class="Sup">®</span></span>, a registered trademark of PDR Network. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. There are no specific antidotes for VERSACLOZ. </p>
<p>In managing overdosage, consider the possibility of multiple-drug involvement.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_a2eb0438-558c-41b3-8044-a8f49cf855c1"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VERSACLOZ, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5<span class="Italics">H</span>-dibenzo[<span class="Italics">b,e</span>][1,4]diazepine.</p>
<p>The structural formula is: </p>
<div class="Figure">
<a name="id1952"></a><img alt="8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-03.jpg">
</div>
<p>VERSACLOZ is available as a free-flowing yellow suspension. Each mL contains 50 mg of clozapine.</p>
<p>The active component of VERSACLOZ is clozapine. The remaining components are glycerin, sorbitol (non-crystallizing), sodium dihydrogen phosphate dihydrate, xanthan gum, sodium methylparaben, sodium propylparaben, povidone, water, and sodium hydroxide to adjust to a pH range of 6.5 – 7.0. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_6e94a163-5d76-4468-a469-38e48e83a3a3"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_227b0c5c-fcc5-4d4a-97bb-edcc38d07080"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> is mediated through antagonism of the dopamine type 2 (D<span class="Sub">2</span>) and the serotonin type 2A (5-HT<span class="Sub">2A</span>) receptors. VERSACLOZ also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_0e39bbce-4533-4b74-a024-c7f8773c106e"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clozapine demonstrated binding affinity to the following receptors: histamine H<span class="Sub">1</span> (K<span class="Sub">i</span> 1.1 nM), adrenergic α<span class="Sub">1A</span> (K<span class="Sub">i </span>1.6 nM), serotonin 5-HT<span class="Sub">6</span> (K<span class="Sub">i</span> 4 nM<span class="Bold">)</span>, serotonin 5-HT<span class="Sub">2A</span> (K<span class="Sub">i</span> 5.4 nM), muscarinic M<span class="Sub">1</span> (K<span class="Sub">i </span>6.2 nM), serotonin 5-HT<span class="Sub">7</span> (K<span class="Sub">i</span> 6.3 nM), serotonin 5-HT<span class="Sub">2C</span> (K<span class="Sub">i</span> 9.4 nM), dopamine D<span class="Sub">4</span> (K<span class="Sub">i </span>24 nM), adrenergic α<span class="Sub">2A</span> (K<span class="Sub">i </span>90 nM), serotonin 5-HT<span class="Sub">3  </span>(K<span class="Sub">i </span> 95 nM), serotonin 5-HT<span class="Sub">1A</span> (K<span class="Sub">i</span> 120 nM), dopamine D<span class="Sub">2</span> (K<span class="Sub">i</span> 160 nM), dopamine D<span class="Sub">1</span> (K<span class="Sub">i</span> 270 nM), dopamine D<span class="Sub">5</span> (K<span class="Sub">i</span> 454 nM), and dopamine D<span class="Sub">3</span> (K<span class="Sub">i</span> 555 nM). </p>
<p>Clozapine causes little or no prolactin elevation.</p>
<p>Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_22bd5743-a10e-4717-97f2-091d25a3e537"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics"><span class="Underline">Absorption</span></span></p>
<p>In man, clozapine tablets (25 mg and 100 mg) are equally bioavailable relative to a clozapine solution. VERSACLOZ Oral Suspension is bioequivalent to clozapine marketed tablets. </p>
<p>Following oral administration of 100 mg to 800 mg VERSACLOZ, once daily, the average steady-state peak plasma concentration was 275 ng/mL (range: 105 - 723 ng/mL), occurring at the average of 2.2 hours (range: 1 to 3.5 hours) after dosing. The average minimum concentration at steady-state was 75 ng/mL (range: 11 to 198 ng/mL).</p>
<p>When VERSACLOZ was administered after a high fat meal there was no effect on the AUC<span class="Sub">ss</span> or C<span class="Sub">min, ss</span>, however C<span class="Sub">max</span> was reduced about 20%, and there was a slight delay in T<span class="Sub">max</span> of 0.5 hour from a median T<span class="Sub">max </span>of 2.0 hours under fasted conditions to 2.5 hours under fed conditions. The decrease in C<span class="Sub">max</span> is not considered clinically relevant. Therefore VERSACLOZ may be taken without regard to meals. </p>
<p><span class="Underline">Distribution</span></p>
<p>Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important <span class="Italics">[see <a href="#i4i_interactions_id_da25aa97-56f6-49bf-9c76-844d45424922">Drug Interactions (7)</a>].</span></p>
<p><span class="Underline">Metabolism and Excretion</span></p>
<p>VERSACLOZ is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. VERSACLOZ is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and <span class="Italics">N</span>-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and <span class="Italics">N</span>-oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range:  4-12 hours), compared to a mean elimination half-life of 12 hours (range: 4-66 hours), after achieving steady-state with 100 mg twice daily dosing.</p>
<p>A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady-state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.</p>
<p><span class="Italics"><span class="Underline">Drug-Drug Interaction Studies</span></span></p>
<p><span class="Underline">Fluvoxamine </span></p>
<p>A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, <span class="Italics">N</span>-desmethylclozapine and clozapine <span class="Italics">N</span>-oxide, were elevated about three-fold compared to baseline steady-state concentrations. </p>
<p><span class="Underline">Paroxetine, Fluoxetine, and Sertraline</span></p>
<p>In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline. </p>
<p><span class="Italics"><span class="Underline">Specific Population Studies</span></span></p>
<p><span class="Underline">Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>No specific pharmacokinetic studies were conducted to investigate the effects of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of clozapine. Higher clozapine plasma concentrations are likely in patients with significant renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when given usual doses.</p>
<p><span class="Underline">CYP2D6 Poor Metabolizers</span></p>
<p>A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_303ed90d-ed7d-4a05-a0c5-9f404b4721d4"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d3a37ec6-a48b-4be3-9211-1fd39831d1cf"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics"><span class="Underline">Carcinogenesis</span></span></p>
<p>No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m<span class="Sup">2</span> body surface area basis. </p>
<p><span class="Italics"><span class="Underline">Mutagenesis</span></span></p>
<p>Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the <span class="Italics">in vitro</span> mammalian V79 in Chinese hamster cells, the <span class="Italics">in vitro </span>unscheduled DNA synthesis in rat hepatocytes, or the <span class="Italics">in vivo </span>micronucleus assay in mice.</p>
<p><span class="Italics"><span class="Underline">Impairment of Fertility</span></span></p>
<p>Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight, or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m<span class="Sup">2</span> body surface area basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_0e409e36-061d-40ad-9d78-d15bc33bbce3"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1165a096-9a8b-42cb-a62f-f99ede2555d7"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Treatment-Resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First">The efficacy of clozapine in treatment-resistant <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions – Severity Scale score of at least 4 (moderately ill).</p>
<p>In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with clozapine (N=126) or chlorpromazine (N=142). The maximum daily clozapine dose was 900 mg; the mean daily dose was &gt;600 mg). The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was &gt;1200 mg.</p>
<p>The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of <span class="Underline">&lt;</span>3 (mildly ill), or (2) a BPRS score of <span class="Underline">&lt;</span>35, at the end of 6 weeks of treatment. Approximately 88% of patients from the clozapine and chlorpromazine groups completed the 6-week trial. At the end of six weeks, 30% of the clozapine group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p&lt;0.001). The mean change in total BPRS score was -16 and -5 in the clozapine and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the clozapine and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the clozapine and chlorpromazine group, respectively. These changes in the clozapine group were statistically significantly greater than in the chlorpromazine group (p&lt;0.001 in each analysis).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f390cb8d-d78a-45d1-9f52-9269e58c9d79"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span></h2>
<p class="First">The effectiveness of clozapine in reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> was assessed in the International <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Prevention Trial (InterSePT™, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of clozapine (Clozaril<span class="Sup">®</span>) versus olanzapine (Zyprexa<span class="Sup">®</span>, a registered trademark of Eli Lilly and Company) in 956 patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span> (DSM-IV) who were judged to be at risk for recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met one of the following criteria:</p>
<dl>
<dt>•</dt>
<dd>They had <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span> within the three years prior to their baseline evaluation.</dd>
<dt>•</dt>
<dd>They had been hospitalized to prevent a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> within the three years prior to their baseline evaluation.</dd>
<dt>•</dt>
<dd>They demonstrated moderate-to-severe <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> with a depressive component within one week prior to their baseline evaluation.</dd>
<dt>•</dt>
<dd>They demonstrated moderate-to-severe <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> accompanied by command <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> to do self-harm within one week prior to their baseline evaluation.</dd>
</dl>
<p>Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200–900 mg/day for clozapine and 5–20 mg/day for olanzapine. For the 956 patients who received clozapine or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.</p>
<p>The primary efficacy measure was time to (1) a significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, including a <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>; (2) hospitalization due to imminent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening? or “very much worsening? from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Monitoring Board (SMB), a group of experts blinded to patient data.</p>
<p>A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, and the remainder (38%) were diagnosed with <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>. Only about one-fourth of the total patient population (27%) was identified as “treatment-resistant? at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range: 18–69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of “other? races.</p>
<p>Patients treated with clozapine had a statistically significant longer delay in the time to recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> and not a demonstration of the superior efficacy of clozapine over olanzapine.</p>
<p>The probability of experiencing (1) a significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, including a <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>, or (2) hospitalization because of imminent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).</p>
<p><span class="Bold">Figure 1. Cumulative Probability of a Significant <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">Suicide Attempt</span> or Hospitalization to Prevent <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> in Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span> at High Risk of Suicidality</span></p>
<div class="Figure">
<a name="id2140"></a><img alt="Figure-02 Cumulative Probability" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-04.jpg">
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bdfbd227-fe01-467e-859d-e780f29b5206"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2da60eb-57d1-4ac4-8919-f0d759ee7cba"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First"><span class="Italics"><span class="Underline">Oral Suspension</span></span></p>
<p>Free-flowing, yellow suspension (50 mg/mL) in amber bottle containing 100 mL. Each box contains 1 x 1 mL oral syringe, 1 x 9 mL oral syringe and 1 bottle adaptor.</p>
<p>NDC No. 18860-121-01</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40398991-668d-40f3-afed-aa06c7728302"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store VERSACLOZ at or below 25°C (77°F). Do not refrigerate or freeze. Protect from light. Shake well for 10 seconds before use.</p>
<p>The suspension is stable for 100 days after initial bottle opening.</p>
<p>Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_d0395815-f311-49e9-b082-0d989ba2b3ae"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information and Instructions for Use).</p>
<p>Discuss the following issues with patients and caregivers:</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></span></dd>
<dt>•</dt>
<dd>Instruct patients (and caregivers) beginning treatment with VERSACLOZ about the risk of developing severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt>•</dt>
<dd>Instruct patients to immediately report to their physician any symptom or sign of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., flu-like illness; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>; general <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; mucus membrane ulceration; skin, pharyngeal, vaginal, urinary, or pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; or extreme <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>) occurring at any time during VERSACLOZ therapy, to aid in evaluation for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and to institute prompt and appropriate management <span class="Italics">[see <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1)</a>, (<a href="#i4i_section_id_18276b32-9318-48bf-b5b5-2141660e9fca">5.10</a>), and (<a href="#i4i_section_id_875c48ff-3ac3-4a1b-9d62-5149b804f87a">5.11</a>)]</span>.</dd>
<dt>•</dt>
<dd>Inform patients and caregivers VERSACLOZ is available only through a restricted program called the Clozapine REMS Program designed to ensure the required blood monitoring, in order to reduce the risk of developing severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Advise patients and caregivers of the importance of having blood tested as follows:<dl>
<dt>•</dt>
<dd>Weekly blood tests are required for the first 6 months.</dd>
<dt>•</dt>
<dd>An ANC is required every 2 weeks for the next 6 months if an acceptable ANC is maintained during the first 6 months of continuous therapy.</dd>
<dt>•</dt>
<dd>An ANC is required once every 4 weeks thereafter if an acceptable ANC is maintained during the second 6 months of continuous therapy.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>VERSACLOZ is available only from certified pharmacies participating in the program. Provide patients (and caregivers) with website information and the telephone number on how to obtain the product.</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span>: </span>Inform patients and caregivers about the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the period of initial dose titration. Instruct them to strictly follow the clinician’s instructions for dosage and administration. Advise patients to consult their clinician immediately if they feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lose consciousness or have signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> <span class="Italics">[see <a href="#i4i_section_id_981b9878-aa5b-4736-b614-4687936cee84">Dosage and Administration (2.2)</a> and <a href="#i4i_section_id_6bc8f5dd-85d1-461e-a81d-c81d9671f6f6">Warnings and Precautions (5.3)</a>]</span>.</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span>: </span>Inform patients and caregivers about the significant risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during VERSACLOZ treatment. Caution them about driving and any other potentially hazardous activity while taking VERSACLOZ <span class="Italics">[see <a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">Warnings and Precautions (5.4)</a>]</span>. </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">QT Interval Prolongation</span>: </span>Advise patients to consult their clinician immediately if they feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lose consciousness, or have signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Instruct patients to not take VERSACLOZ with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking VERSACLOZ before any new drug <span class="Italics">[see <a href="#i4i_section_id_2abb5581-d2b8-4aa2-b803-4e5cf73a4e7b">Warnings and Precautions (5.8)</a> and <a href="#i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb">Drug Interactions (7.1)</a>]</span>. </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Metabolic Changes (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>)</span>:</span> Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and cardiovascular reactions. Educate patients and caregivers about the symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (high blood sugar) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Monitor all patients for these symptoms. Patients who are diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or have risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (<span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> should have assessments of fasting glucose. Clinical monitoring of weight is recommended <span class="Italics">[see <a href="#i4i_section_id_0a9539f5-21b9-4a5b-9c3f-d6860b44ac46">Warnings and Precautions (5.9)</a>]</span>. </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Interference with Cognitive and Motor Performance</span>: </span>Because VERSACLOZ may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that VERSACLOZ therapy does not affect them adversely <span class="Italics">[see <a href="#i4i_section_id_5f1218f8-ee95-41e3-9999-64e3a0d73782">Warnings and Precautions (5.14)</a>]</span>.</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Missed Doses and Re-Initiating Treatment</span>: </span>Inform patients and caregivers that if the patient misses taking VERSACLOZ for more than 2 days, they should not restart his or her medication at the same dosage but should contact their physician for dosing instructions <span class="Italics">[see <a href="#i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803">Dosage and Administration (2.6)</a> and <a href="#i4i_section_id_05ecf222-5a1d-49d8-b0f3-8aa6392bcd0e">Warnings and Precautions (5.1</a>, <a href="#i4i_section_id_65016aaa-9283-4747-9c10-35d0049bff7d">5.3</a>)].</span>
</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Pregnancy</span>: </span>Patients and caregivers should notify the clinician if the patient becomes pregnant or intends to become pregnant during therapy <span class="Italics">[see <a href="#i4i_pregnancy_id_8a7bad36-b81d-4c50-a11d-401fa6ee090c">Use in Specific Populations (8.1)</a>].</span>
</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Nursing</span>: </span>Advise patients and caregivers that the patient should not breast feed an infant if she is taking VERSACLOZ <span class="Italics">[see <a href="#i4i_nursing_mothers_id_cdbdf840-e375-478d-9926-daa624f42b98">Use in Specific Populations (8.3)</a>].</span>
</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Concomitant Medication</span>: </span>Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions <span class="Italics">[see <a href="#i4i_section_id_9e01bbee-2c17-4f67-a5c5-8fec09fff803">Dosage and Administration (2.6)</a>, <a href="#i4i_section_id_c126c442-5966-457c-9d9e-8eadca9202bb">Drug Interactions (7.1)</a>, and Table 1]</span>.</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="Underline">Patient Instructions for Use</span>: </span>Educate the patient and caregiver about the Patient Instructions for Use if VERSACLOZ will be administered at home. Discuss the specific steps for administering the prescribed dose using the oral syringe <span class="Italics">[see <a href="#i4i_section_id_d03dec5d-446e-4f17-92f7-a1035c497719">Dosage and Administration (2.3)</a>].</span>
</dd>
</dl>
<p>Distributed by:<br><span class="Bold">Jazz Pharmaceuticals, Inc. </span><br>Palo Alto, CA 94304</p>
<p>U.S. Patent No. 8057811</p>
<p>VERSACLOZ<span class="Sup">®</span> is a trademark of Jazz Pharmaceuticals plc or its subsidiaries. <br><br>Revised: September 2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_daf42097-5472-4917-8ef6-624145c375a7"></a><a name="section-16"></a><p></p>
<h1>Patient Information  </h1>
<p class="First"><span class="Bold">VERSACLOZ<span class="Sup">®</span> (VER sa kloz) </span></p>
<p><span class="Bold">(clozapine) </span></p>
<p><span class="Bold">Oral Suspension</span></p>
<p>Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about VERSACLOZ? </span></p>
<p><span class="Bold">VERSACLOZ can cause serious side effects, including:</span></p>
<p><span class="Bold">1. Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, a <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span> that can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> means that you do not have enough of certain white blood cells to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Tell your healthcare provider right away if you have any of the following symptoms or signs of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: </p>
<dl>
<dt>•</dt>
<dd>Skin, throat, urinary tract, vaginal, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, or any other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></dd>
<dt>•</dt>
<dd>Sores or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> inside your mouth, gums or on your skin</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span> that take a long time to heal</dd>
<dt>•</dt>
<dd>Feel like you have the flu</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or burning while urinating</dd>
<dt>•</dt>
<dd>Unusual <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></dd>
<dt>•</dt>
<dd>Sores or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in or around your rectal area</dd>
<dt>•</dt>
<dd>Feel extremely tired or weak</dd>
</dl>
<p>If you have symptoms of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> you will need to have a blood test right away to check if VERSACLOZ is causing your symptoms. You must have frequent blood tests while taking VERSACLOZ so your healthcare provider can make sure you are not getting severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>VERSACLOZ is available only through a restricted program called the Clozapine REMS Program. This program makes sure that <span class="Bold">you will receive each refill of VERSACLOZ only if you have a blood test and your blood test result is acceptable to your healthcare provider.</span></p>
<p>During your first 6 months of clozapine treatment, you will have weekly blood tests. If you have not taken clozapine before, you will need weekly blood tests when you first start VERSACLOZ. If you have acceptable blood test results during your first 6 months of clozapine treatment, you can have a blood test every other week for the next 6 months. After a year of acceptable blood test results, you can have blood tests every 4 weeks while you are taking VERSACLOZ.</p>
<p><span class="Bold">2. Decreased blood pressure (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>), slow heart rate (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>), or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>) that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> caused by a sudden change in your heart rate and blood pressure when you rise too quickly from a sitting or lying position can happen while you take VERSACLOZ and can be life threatening. These problems may happen more often when you are first starting treatment with VERSACLOZ or when your dose is increased. Tell your healthcare provider right away if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lose consciousness, or have symptoms of slow heart rate or an irregular heart rhythm.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> can occur during VERSACLOZ treatment.</span> Be especially careful while driving or during any other dangerous activity while taking VERSACLOZ.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span> (heart <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">muscle inflammation</span>) and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> (heart <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>) that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> Symptoms of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> include:</p>
<div class="Figure">
<a name="id-1163623658"></a><img alt="symptoms of <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-01.jpg">
</div>
<p><span class="Bold">5. Higher risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in elderly people with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span> (<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>) or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. </span>VERSACLOZ can increase the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in elderly people who have <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. VERSACLOZ is not for treating <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> in elderly people with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</p>
<p><span class="Bold">What is VERSACLOZ?</span></p>
<p>VERSACLOZ is a prescription antipsychotic medicine used to treat people with certain types of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, including people who:</p>
<dl>
<dt>•</dt>
<dd>are not helped by other <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> medicines</dd>
<dt>•</dt>
<dd>have been suicidal and may be at risk of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> again </dd>
</dl>
<p>It is not known if VERSACLOZ is safe and effective in children.</p>
<p><span class="Bold">Who should not take VERSACLOZ?</span></p>
<p><span class="Bold">Do not take VERSACLOZ if you:</span></p>
<dl>
<dt>•</dt>
<dd>have blood problems called <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
<dt>•</dt>
<dd>are allergic to clozapine or any of the ingredients in VERSACLOZ. See the end of this Patient Information Leaflet for a complete list of ingredients in VERSACLOZ.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking VERSACLOZ?</span></p>
<p>Before you take VERSACLOZ, tell your healthcare provider about all of your medical conditions, including if you:</p>
<dl>
<dt>•</dt>
<dd>have or have had heart problems or a family history of heart problems including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, abnormal heart rhythm, or <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> </dd>
<dt>•</dt>
<dd>have or have had liver or kidney problems</dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> </dd>
<dt>•</dt>
<dd>have or have had low levels of potassium or magnesium in your blood</dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>•</dt>
<dd>have increased pressure in your eyes (<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>)</dd>
<dt>•</dt>
<dd>have had <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</dd>
<dt>•</dt>
<dd>have or have had uncontrolled movements of your tongue, face, mouth, or jaw (<span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>)</dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>•</dt>
<dd>have or have had an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> gland </dd>
<dt>•</dt>
<dd>smoke tobacco</dd>
<dt>•</dt>
<dd>plan to stop smoking tobacco while taking VERSACLOZ</dd>
<dt>•</dt>
<dd>use products containing caffeine </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if VERSACLOZ will harm your unborn baby. Call your healthcare provider right away if you become pregnant while taking VERSACLOZ.</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. VERSACLOZ can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take VERSACLOZ. Do not breastfeed while taking VERSACLOZ.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p>VERSACLOZ and other medicines may affect each other causing side effects.</p>
<p>Especially tell your healthcare provider if you take: </p>
<dl>
<dt>•</dt>
<dd>chemotherapy, radiation, or other medicines that cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, low white blood cell count, or affect your bone marrow </dd>
<dt>•</dt>
<dd>other antipsychotics or other medicines that can affect the amount of clozapine in your blood </dd>
<dt>•</dt>
<dd>medicines used to treat <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, relax your muscles, or help you sleep</dd>
<dt>•</dt>
<dd>any medicines that make you feel <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span></dd>
<dt>•</dt>
<dd>antibiotics</dd>
<dt>•</dt>
<dd>medicines used to treat heart problems</dd>
<dt>•</dt>
<dd>medicines used to lower the amount of water in your body (diuretics)</dd>
<dt>•</dt>
<dd>medicines used for birth control </dd>
</dl>
<p>Ask your healthcare provider for a list of these medicines if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take VERSACLOZ?</span></p>
<dl>
<dt>•</dt>
<dd>Read the “<span class="Bold">Instructions for Use</span>? at the end of this Patient Information for specific information about the right way to use VERSACLOZ. </dd>
<dt>•</dt>
<dd>Your pharmacist should go over the instructions for how to use VERSACLOZ with you when you receive your first prescription.</dd>
<dt>•</dt>
<dd>Take VERSACLOZ exactly as your healthcare provider tells you to take it. Talk to your healthcare provider or pharmacist if you are not sure how to take VERSACLOZ.</dd>
<dt>•</dt>
<dd>Do not change your dose or stop taking VERSACLOZ without talking to your healthcare provider.</dd>
</dl>
<p><span class="Bold">The symptoms of VERSACLOZ <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> can include:</span></p>
<div class="Figure">
<a name="id-188454535"></a><img alt="symptoms" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-02.jpg">
</div>
<p>If you miss a dose of VERSACLOZ for more than 2 days, check with your healthcare provider before starting to take it again to make sure you take the correct dose.</p>
<p><span class="Bold">What should I avoid while taking VERSACLOZ?</span></p>
<dl>
<dt>•</dt>
<dd>You should not drink alcohol while taking VERSACLOZ. It can increase your chances of getting serious side effects. </dd>
<dt>•</dt>
<dd>Do not drive, operate machinery, swim, climb, or do other dangerous   activities until you know how VERSACLOZ affects you.  </dd>
</dl>
<p><span class="Bold">What are the possible side effects of VERSACLOZ?</span></p>
<p><span class="Bold">VERSACLOZ may cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>See <span class="Bold">"What is the most important information I should know about VERSACLOZ?"</span>
</dd>
<dt>•</dt>
<dd><span class="Bold">high count of a certain white blood cell (<span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>)</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">problems with your heartbeat. These heart problems can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Call your healthcare provider right away if you have any of these symptoms:</span><dl>
<dt>•</dt>
<dd>passing out or feeling like you will pass out</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd>feeling as if your heart is pounding or missing beats</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold">high blood sugar (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) and changes in the fat levels in your blood (<span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>)</span></dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS).</span> NMS is a rare but very serious problem that can happen in people who take VERSACLOZ. NMS can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in a hospital. Call your healthcare provider right away if you become severely ill and have any of these symptoms: <dl>
<dt>•</dt>
<dd>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>•</dt>
<dd>excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt>•</dt>
<dd>stiff muscles</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
<dt>•</dt>
<dd>changes in your breathing, heartbeat and blood pressure</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </span>Some people may have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> that comes and goes while they take VERSACLOZ. This happens more often in the first 3 weeks you take VERSACLOZ. Talk to your healthcare provider if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.   </dd>
<dt>•</dt>
<dd>
<span class="Bold">blood clot in your lung (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>) or in the veins of your legs (deep-vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>). </span>Get emergency help right away if you have symptoms of a blood clot including:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your leg, ankle or foot</dd>
<dt>•</dt>
<dd>warm feeling in the skin of your affected leg</dd>
<dt>•</dt>
<dd>changes in your skin color such as turning <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> or blue</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold">a problem that includes <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, increased pulse rate and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (anticholinergic toxicity) </span></dd>
<dt>•</dt>
<dd><span class="Bold">problems thinking clearly and moving your body</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">uncontrolled movements of your tongue, face, mouth, or jaw</span> (<span class="Bold"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>)</span>
</dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in elderly people (cerebrovascular problems)</span></dd>
</dl>
<p>The most common side effects of VERSACLOZ include:</p>
<div class="Figure">
<a name="id-599711182"></a><img alt="side effects" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-22.jpg">
</div>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of VERSACLOZ. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store VERSACLOZ?</span></p>
<dl>
<dt>•</dt>
<dd>Store VERSACLOZ at room temperature between 68°F to 77°F (20°C to 25°C). </dd>
<dt>•</dt>
<dd>Do not refrigerate or freeze VERSACLOZ. </dd>
<dt>•</dt>
<dd>Protect VERSACLOZ from light. </dd>
<dt>•</dt>
<dd>Shake your VERSACLOZ bottle well for 10 seconds before each use.</dd>
</dl>
<p><span class="Bold">Keep VERSACLOZ and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of VERSACLOZ</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use VERSACLOZ for a condition for which it was not prescribed. Do not give VERSACLOZ to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Patient Information Leaflet summarizes the most important information about VERSACLOZ. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for more information about VERSACLOZ that is written for healthcare professionals.</p>
<p>For more information, go to <a href="#_Ref">www.VERSACLOZ.com</a> or call 1-800-520-5568.</p>
<p><span class="Bold">What are the ingredients in VERSACLOZ?</span></p>
<p>Active ingredient: clozapine</p>
<p>Inactive ingredients: glycerin, sorbitol (non-crystallizing), sodium dihydrogen phosphate dihydrate, xanthan gum, sodium methylparaben, sodium propylparaben, povidone, water, and sodium hydroxide</p>
<p><span class="Bold">Instructions for Use</span></p>
<p><span class="Bold">VERSACLOZ<span class="Sup">®</span> (VER sa kloz)</span></p>
<p><span class="Bold">(clozapine)</span></p>
<p><span class="Bold">Oral Suspension </span></p>
<p><span class="Bold">Supplies you will need to take your VERSACLOZ dose:</span></p>
<dl>
<dt>•</dt>
<dd>VERSACLOZ<span class="Sup">®</span> Oral Suspension bottle</dd>
<dt>•</dt>
<dd>a bottle neck adaptor</dd>
<dt>•</dt>
<dd>the correct oral syringe to measure your dose<dl>
<dt>•</dt>
<dd>
<span class="Bold">If your dose is 1 mL (50 mg) or less</span>, use the smaller 1 mL oral syringe.</dd>
<dt>•</dt>
<dd>
<span class="Bold">If your dose is more than 1 mL (50 mg),</span> use the larger 9 mL oral syringe.</dd>
</dl>
</dd>
</dl>
<div class="Figure">
<a name="id2550"></a><img alt="Figure-03 Patient Use" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-05.jpg">
</div>
<div class="Figure">
<a name="id2551"></a><img alt="Figure A Step 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-06.jpg">
</div>
<div class="Figure">
<a name="id2552"></a><img alt="Figure B Step 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-07.jpg">
</div>
<div class="Figure">
<a name="id2553"></a><img alt="Figure C Step 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-08.jpg">
</div>
<div class="Figure">
<a name="id2554"></a><img alt="Figure D-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-09.jpg">
</div>
<div class="Figure">
<a name="id2555"></a><img alt="Figure D-02 Step 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-10.jpg">
</div>
<div class="Figure">
<a name="id2556"></a><img alt="Figure E Step 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-11.jpg">
</div>
<div class="Figure">
<a name="id2557"></a><img alt="Figure F Step 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-12.jpg">
</div>
<div class="Figure">
<a name="id2558"></a><img alt="Figure G Step 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-13.jpg">
</div>
<div class="Figure">
<a name="id2559"></a><img alt="Figure H Step 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-14.jpg">
</div>
<div class="Figure">
<a name="id2560"></a><img alt="Figure I Step 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-15.jpg">
</div>
<div class="Figure">
<a name="id2561"></a><img alt="Figure J Step 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-16.jpg">
</div>
<div class="Figure">
<a name="id2562"></a><img alt="Figure K Step 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-17.jpg">
</div>
<div class="Figure">
<a name="id2563"></a><img alt="Figure L Step 12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-18.jpg">
</div>
<div class="Figure">
<a name="id2564"></a><img alt="Figure M Step 13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-19.jpg">
</div>
<div class="Figure">
<a name="id2565"></a><img alt="Figure N Step 14" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-20.jpg">
</div>
<p><span class="Bold">Disposal of your oral syringe, empty VERSACLOZ bottle and bottle neck adaptor:</span></p>
<p>Place the cap back on the empty VERSACLOZ bottle before you throw it away. The oral syringe, empty bottle and bottle neck adaptor should be placed in your household trash when you finish your bottle of VERSACLOZ. The oral syringe should not be shared with other people or used for medicines other than VERSACLOZ.</p>
<p>Distributed by:</p>
<p><span class="Bold">Jazz Pharmaceuticals, Inc.</span></p>
<p>Palo Alto, CA 94304 USA</p>
<p>This Patient Information and the Instructions for Use have been approved by the U.S. Food and Drug Administration.</p>
<p>Revised: September 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_035f65fa-1004-4fc5-b1ef-cc4d7ca4bf76"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL-Container Label</h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Versacloz<span class="Sup">®</span></span></p>
<p>(clozapine) Oral Suspension</p>
<p><span class="Bold">50 mg/mL</span></p>
<div class="Figure">
<a name="id2673"></a><img alt="Z:\SPL\Versacloz SPL\2015-09-29 SPL minor change - date\replacement image\cdf2b2f4-f6aa-4683-9232-68b8871295a0-21.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1&amp;name=image-21.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VERSACLOZ 		
					</strong><br><span class="contentTableReg">clozapine suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:18860-121</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOZAPINE</strong> (CLOZAPINE) </td>
<td class="formItem">CLOZAPINE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:18860-121-01</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203479</td>
<td class="formItem">02/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Jazz Pharmaceuticals, Inc.
							(135926363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmaceutics International, Inc.</td>
<td class="formItem"></td>
<td class="formItem">878265586</td>
<td class="formItem">MANUFACTURE(18860-121), PACK(18860-121)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3fcfd8db-5e57-48eb-8c21-d8f4919a9717</div>
<div>Set id: 693cb9d4-39db-4ecf-9eae-b01f06f8d5d1</div>
<div>Version: 7</div>
<div>Effective Time: 20150930</div>
</div>
</div> <div class="DistributorName">Jazz Pharmaceuticals, Inc.</div></p>
</body></html>
